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Summary
 
Two cell permeable peptide fluoromethyl ketone inhibitors of Interleukin-1
 
b
 
 converting en-
zyme (ICE) family proteases were tested as inhibitors of apoptotic cell death of T lymphocytes
at various stages of differentiation. The CPP-32–like protease activity in apoptotic cell lysates
was blocked by both the ICE inhibitor Cbz-Val-Ala-Asp(OMe)-fluoromethyl ketone (ZVAD-
FMK) as well as its truncated analog Boc-Asp(OMe)-fluoromethyl ketone (BD-FMK), which
failed to block ICE. In vitro apoptotic death in murine thymocytes triggered by the indepen-
dent agents dexamethasone, etoposide, radiation, anti-Fas, and anti-CD3 was blocked equally
well by BD-FMK and ZVAD-FMK, but not by the control reagent Cbz-Phe-Ala-fluorome-
thyl ketone. In activated T cell blasts, while anti-CD3/ Fas-induced death was almost com-
pletely inhibited by both ZVAD-FMK and BD-FMK, death induced by dexamethasone, eto-
poside, or irradiation was more sensitive to inhibition by BD-FMK. In the murine T cell line
CTLL-2, apoptotic death induced by IL-2 withdrawal, etoposide, or dexamethasone was in-
hibited by BD-FMK, while ZVAD-FMK was without effect. These data indicate that ICE-
family proteases comprise a common functional step in distinct T cell apoptotic death path-
ways, but suggest that different family members are likely to be critical in various differentiated
T cell types, even when triggered by the same stimulus.
 
W
 
hile programmed cell death has become recognized
as an important component of normal development
and immune function, the biochemical pathways leading
to such cell death remain poorly defined. However, the
recent demonstration that the nematode death gene 
 
ced-3
 
encodes a cysteine protease related to the mammalian inter-
leukin-1
 
b
 
 converting enzyme (ICE) has led to the iden-
tification of a family of cysteine proteases related by se-
quence homology (1). This ICE-family of proteases has an
unusual substrate cleavage specificity for aspartic acid resi-
dues at the P1 position. Studies of sequence homology and
fine specificity of substrate cleavage suggest there are two to
three subfamilies (2, 3): The ICE-like subfamily prefers sub-
strates with hydrophobic amino acids at P4 (such as Tyr-Val-
Ala-Asp [YVAD]), the CPP-32–like subfamily has less se-
quence homology to ICE and prefers substrates with acidic
amino acids at P4 (such as Asp-Glu-Val-Asp [DEVD]), and
a potential ICH-1–like subfamily remains poorly character-
ized. In the case of death induced by Fas cross-linking, there is
evidence for a proteolytic cascade involving sequential acti-
vation of ICE-like enzymes and CPP-32–like enzymes (4, 5).
Convincing evidence for a functional role of ICE family
proteases in programmed cell death has come from several
strategies designed to selectively inactivate these proteases, par-
ticularly the expression of the virally encoded protein in-
hibitors CrmA and Baculovirus p35 (reviewed in reference
1). Peptide-based inhibitors of ICE family proteases have
also been shown to block apoptotic death in vivo and in vitro,
but their membrane permeability is sometimes a problem, and
their specificity has not always been adequately established.
We report here the ability of two newly developed cell
permeant peptide-fluoromethyl ketone inhibitors of ICE
family proteases to specifically block in vitro apoptotic death
processes in T lymphocytes triggered by different input
pathways. These results indicate that this protease family
comprises a common downstream step in apoptotic T cell
death pathways. The ICE inhibitor Cbz-Val-Ala-Asp(OMe)-
fluoromethyl ketone (ZVAD-FMK) specifically blocks most
examples of T lymphocyte apoptotic death. However, sev-
eral examples of T cell death which are resistant to ZVAD-
FMK were blocked by the homologous inhibitor BD-
FMK, which blocks CPP-32–like proteases but not ICE.
These results suggest that for a single apoptotic stimulus,
different members of the ICE family are functionally im-
portant in different types of T cells, and show the use of
peptide-FMK reagents as probes of the role of ICE family
proteases in in vitro cell death systems.
 
Materials and Methods
 
Reagents.
 
The protease inhibitors Cbz-Val-Ala-Asp-(OMe)-
fluoromethyl ketone (ZVAD-FMK), Boc-Asp(OMe)-fluorome-
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thyl ketone (BD-FMK), Cbz-Asp(OMe)-Glu(OMe)-Val-Asp
(OMe)-fluoromethyl ketone (ZDEVD-FMK), Cbz-Phe-Ala-fluo-
romethyl ketone (ZFA-FMK), Cbz-Ala-Ala-Asp-chloromethyl
ketone (ZAAD-CMK) and the CPP-32 substrate Cbz-Asp-
Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin (ZDEVD-AFC)
were purchased from Enzyme Systems Products (Dublin, CA),
dissolved as stock solutions of 50 mM in DMSO, and stored at
 
2
 
70
 
8
 
C. Fixed 
 
Staphylococcal aureus
 
 (Sansorbin) was obtained from
Calbiochem Corp. (La Jolla, CA). Polyclonal anti–human IL-1
 
b
 
was purchased from R&D Systems Inc. (Minneapolis, MN),
mouse anti–human Fas (CH-11) from Upstate Technologies Inc.
(Waltham, MA), and hamster anti–mouse Fas (Jo2) from Phar-
Mingen (San Diego, CA). Dexamethasone, etoposide (VP16), and
Hoechst 33342 were obtained from Sigma Chemical Co. (St.
Louis, MO). FITC-Annexin V was purchased from Brand Appli-
cations B. V. (Maastricht, Netherlands).
 
Granzyme B Activity.
 
Granzyme B activity was measured in
detergent extracts of cloned murine CTL, provided by Dr. Mar-
tha Alexander-Miller (National Cancer Institute). Extracts were
prepared by treating 1 
 
3
 
 10
 
7
 
 CTL with 1 ml of 1% Triton X-100
in assay buffer at 0
 
8
 
C for 10 min, followed by centrifugation at
11,000 
 
g
 
 for 10 min. This extract was treated with the haloketone
reagents at the indicated concentrations for 2 h at room tempera-
ture, followed by the activity assay, which was carried out with
1 
 
3
 
 10
 
5
 
 cell equivalents of extract/well in flat-bottom microtiter
plates using Boc-Ala-Ala-Asp-S-benzyl (BAAD-S-Bzl) (Enzyme
Systems Products) at a final concentration of 125 
 
m
 
M in 0.5 M
NaCl, 0.1 M Hepes, 1 mM EDTA, and 0.5 mM 5,5
 
9
 
-dithio-
bis(2-nitrobenzoic acid) DTNB, pH 7.5. Activity was calculated
from initial slopes of plots of A
 
414
 
 versus time, relative to controls
with no inhibitor. 
 
CPP-32-like DEVDase Activity.
 
Jurkat cells (5 
 
3
 
 10
 
6
 
/ml)
were incubated with 1 
 
m
 
g/ml CH-11 anti-Fas IgM on ice for 15
min, and then at 37
 
8
 
C for 45 min. After centrifugation, the cell
pellets were lysed in ICE buffer (1 
 
3
 
 10
 
6
 
 cells in 200 
 
m
 
l 50 mM
Hepes buffer, pH 7.5, 10% sucrose, and 0.1% Triton X-100) for
20 min on ice. After centrifugation at 10,000 
 
g
 
 for 10 min at 4
 
8
 
C,
200 
 
m
 
l of supernatant was transferred to a tube containing 2 
 
m
 
l 1 M
dithiothreitol. Peptide-FMKs were then added at the indicated
concentrations and incubated on ice for 15 min followed by
ZDEVD-AFC to a final concentration of 50 
 
m
 
M. After incuba-
tion at room temperature for 1 h, each tube was diluted with 2 ml
PBS, and fluorescence measured (excitation, 400 nm, emission,
505 nm). With the amount of cell extracts used, DEVD-ase activ-
ity was linear.
 
IL-1
 
b
 
 Processing.
 
IL-1 secretion from blood monocytes was
measured as previously described (6). Briefly, blood was preincu-
bated with peptide-FMKs for one h, followed by addition of 50
 
m
 
c/ml [
 
35
 
S]methionine and fixed 
 
S. aureus
 
 (Sansorbin; Calbio-
chem; 300 
 
m
 
g/ml). After 5 h of incubation at 37
 
8
 
C, supernatants
were immunoprecipitated with anti–IL-1
 
b
 
, and analyzed on 14%
nonreducing SDS gels.
 
Induction of T Cell Death.
 
T cells were obtained from C57Bl/
10 mice (Jackson Laboratory, Bar Harbor, ME). T cell blasts
were generated by activating splenic T cells with PMA (2 ng/ml)
and ionomycin (1 
 
m
 
g/ml) for 48 h, followed by at least 24 h of
culture in complete medium (RPMI-1640 supplemented with
10% FCS, 100 IU penicillin, and 10 
 
m
 
g/ml streptomycin) with 10
U/ml of human recombinant IL-2 (Cetus Corp., Emeryville,
CA). CTLL-2 cells (American Type Culture Collection, Rock-
ville, MD) were carried in complete medium supplemented with 2
U/ml IL-2. The protease inhibitors were added at the initiation of
200 
 
m
 
l cultures in all experiments described.
Thymocyte death was induced by culture (10
 
6
 
/ml complete me-
dium) with the following stimuli: 0.01 
 
m
 
M dexamethasone, 2 
 
m
 
g/ml
etoposide, immobilized anti-CD3, and immobilized anti-Fas, or
they were exposed to 5Gy of 
 
g
 
-irradiation before culture. Immo-
bilized antibodies were precoated on wells (5 
 
m
 
g/ml of 2C11
anti-CD3 or 10 
 
m
 
g/ml of anti-Fas) followed by washing. T cell blasts
(0.5 
 
3
 
 10
 
6
 
/ml of IL-2 containing complete medium) were cul-
tured with 0.1 
 
m
 
M dexamethasone, 2 
 
m
 
g/ml etoposide, and im-
mobilized anti-CD3, or exposed to 5Gy irradiation before culture
to induce apoptotic death by 18 h. CTLL-2 cells (2.5 
 
3
 
 10
 
5
 
/ml)
were cultured in IL-2 containing medium with 5 
 
m
 
g/ml etopo-
side or 50 
 
m
 
M dexamethasone for 18 h to induce death. For IL-2
withdrawal, cells were washed three times in complete medium
and cultured at 0.25 
 
3
 
 10
 
6
 
 cells/ml in the absence or presence of IL-2.
 
Assays of Apoptotic Cell Death.
 
To measure apoptotic nuclear
morphology, cells were harvested and stained with 4 
 
m
 
g/ml Hoechst
33342 for 10 min at 37
 
8
 
C before fluorescence microscopy. Nuclei
were scored as apoptotic if they displayed chromatin condensa-
tion and/or nuclear fragmentation. For propidium iodide stain-
ing, samples were counterstained with 5 
 
m
 
g/ml of propidium io-
dide. A minimum of 200 cells were scored for each data point. In
some experiments membrane damage was quantitated by the try-
pan blue uptake of dead cells.
For analyzing the sub-G
 
0
 
 DNA content, cells were harvested
by centrifugation and the cell pellets resuspended in lysis buffer
(0.1% sodium citrate and 0.1% Triton X-100) containing 50 
 
m
 
g/ml
of propidium iodide. Samples were stored at 4
 
8
 
C for 18 h before
FACScan
 
Ò
 
 analysis using CELL Quest software.
To detect phosphotidylserine exposure on cell membranes,
cells were stained with FITC-Annexin V (25 ng/ml) for 10 min
at room temperature in the dark. Annexin V high cells were mea-
sured on a flowcytometer by gating on FSC/SSC settings for
control untreated cells.
 
Results
 
ZVAD-FMK and BD-FMK Specifically Block ICE family
Proteases, but not Granzyme B.
 
Although appropriate pep-
tide-chloromethyl ketones irreversibly inactivate both serine
and cysteine proteases, the less reactive fluoromethyl ke-
tones are reported to be selective for cysteine proteases (7).
To confirm the selectivity of ZVAD-FMK and BD-FMK
for cysteine proteases, we tested their ability to inactivate
granzyme B, a serine protease recognizing asp-containing
peptides generally similar to those recognized by ICE fam-
ily members. Fig. 1 
 
A
 
 shows that these FMK reagents fail to
detectably inactivate granzyme B in CTL extracts at con-
centrations up to 400 
 
m
 
M. In contrast, ZAAD-CMK
blocks this enzyme, showing that peptide-asp-FMK re-
agents are selective for cysteine over serine proteases as ex-
pected.
Anti-Fas treated Jurkat T cells rapidly acquire a CPP-
32-like ability to cleave DEVD peptide substrates (8), and we
have measured this activity in extracts of such cells using
the fluorogenic substrate AcDEVD-AFC. Fig. 1 
 
B
 
 shows
the effect of peptide-FMKs on this activity. As expected,
the homologous ZDEVD-FMK is a potent inhibitor, with
ZVAD-FMK and BD-FMK also active with about 40 and
150 times less potency, respectively. In contrast, the control 
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ZFA-FMK reagent lacking aspartate at P1 failed to show
significant inhibition.
Fig. 1 
 
C
 
 shows that ZVAD-FMK inhibits the conversion
of pre–IL-1
 
b
 
 (31 kD) to active IL-1
 
b
 
 (17 kD) in mono-
cytes stimulated by 
 
S. aureus.
 
 The shorter reagent BD-
FMK is seen to be at least 100 times less potent in inhibit-
ing this enzyme as is the control reagent ZFA-FMK, lacking
aspartate at the P1 position crucial for recognition by ICE
famliy proteases.
 
Inhibition of Thymocyte Apoptotic Death By ZVAD-FMK
and BD-FMK.
 
Thymocytes provide a well studied model
system for programmed cell death, which can be triggered
in vitro by four independent input pathways: corticoste-
roid, DNA damage by the DNA topoisomerase II inhibitor
etoposide or radiation, anti-Fas, and anti-CD3. Fig. 2 shows
the ability of ZVAD-FMK and BD-FMK to inhibit such
death. 
 
A
 
 shows that the spontaneous development of apop-
totic nuclear morphology at 18 h is 
 
z
 
70% blocked by
100 
 
m
 
M ZVAD-FMK or BD-FMK, but not by an equal
concentration of ZFA-FMK. At this time, there is little
spontaneous death as judged by propidium iodide (PI)
staining (
 
B
 
). Dexamethasone potently induces apoptotic
nuclear morphology, an effect blocked to control levels
by 50 
 
m
 
M ZVAD-FMK or BD-FMK, but unaffected by
ZFA-FMK. Cell death as assessed by PI (
 
B
 
) shows a similar
specific inhibition by both ZVAD-FMK or BD-FMK, but
somewhat more reagent is required to achieve levels of in-
hibition comparable to apoptotic nuclei. 
 
C–F
 
 show the
similar ability of peptide-FMKs to block thymocyte death by
etoposide and 
 
g
 
-irradiation. Previous studies have shown
both these death systems to be dependent on p53 (9). Thy-
mocyte death induced by immobilized anti-Fas antibody
(Fig. 2, 
 
G–H
 
) is also effectively and specifically blocked by
ZVAD-FMK and BD-FMK, confirming the ability of other
ICE inhibitors to block anti-Fas triggered cell death (10,
11). Finally, immobilized anti-CD3 antibody induces some-
what less death in these cells than other stimuli (12), but
both death readouts again showed specific inhibition by
both ZVAD- or BD-FMK(
 
I
 
 and 
 
J
 
). Thus, thymocyte death
triggered by four independent input pathways is specifically
inhibited by peptide-FMK inhibitors of ICE family pro-
teases, with similar titration curves.
 
Diminished Blocking of T Lymphoblast Apoptotic Death by
ZVAD-FMK, but not ZFA-FMK.
 
Upon activation, pe-
ripheral T cells acquire sensitivity to death by TCR cross-
linking. Fig. 3 shows an experiment examining the ability
of peptide-FMK reagents to block T lymphoblast death in-
duced by dexamethasome (
 
A–C
 
), etoposide (
 
D–F
 
), 
 
g
 
-irra-
diation (
 
G–I
 
), and anti-CD3 (
 
J–L
 
). The two independent
measurements of apoptotic nuclear damage gave very simi-
lar results (
 
top two rows
 
). As was the case for thymocytes, the
control ZFA-FMK reagent was without significant effect.
However, for these blasts, the inhibition patterns of ZVAD-
FMK and BD-FMK are significantly different from those
Figure 1. Reactivity of peptide-FMK reagents. (A) BD-FMK and
ZVAD-FMK do not inactivate Granzyme B. Detergent extracts of cloned
murine CTL were used as a source of enzyme with the thiobenzyl ester
BAAD-S-Bzl as substrate. The indicated final concentrations of inhibitors
were preincubated with enzyme for 2 h at 378C before addition of sub-
strate. ZAAD-CMK was tested as a positive control. (B) P1-Asp FMKs
inactivate apoptotic DEVDase from Jurkat. A detergent extract of anti-
Fas–treated Jurkat cells was used as a source of active CPP-32 or similar
ICE family protease with a fluorometric assay of ZDEVD-AFC hydroly-
sis. The indicated concentrations of peptide-FMK reagents were prein-
bucated with the extract at 08C for 15 min before addition of substrate to
begin the assay. (C) Peptide-FMK inhibition of stimulated human mono-
cyte IL-1b processing. An SDS gel of secreted and immunopreciptated
35S-labeled IL-1b is shown. The control lane C received no S. aureus.
The nonspecific band at 22 kD was not seen in all experiments.
Figure 2. ZVAD-FMK and BD-FMK block murine thymocyte death
induced by different agents in vitro. The effects of ZVAD-FMK (circles),
BD-FMK (squares), and ZFA-FMK (triangles) on thymocyte death after 18 h
of culture in the presence of the following: A and B, spontaneous death
(dotted lines) and dexamethasone (solid lines); C and D, etoposide; E and F,
prior g-irradiation; G and H, immobilized anti-Fas; I and J, immobilized
anti-CD3. Cell death was assessed by apoptotic nuclear morphology (top
row) and staining with propidium iodide (bottom row).2448 ICE Family Proteases in Apoptotic T Cell Death
found in thymocytes in several respects: (a) ZVAD-FMK
shows clearly different inhibition patterns with different apop-
totic stimuli, (b) BD-FMK is a generally better blocker of
apoptotic nuclear damage and cell death measured by
membrane integrity than is ZVAD-FMK, and (c) with dex-
amethasone and irradiation, BD-FMK prevented apoptotic
nuclear damage in some cells which nevertheless died as as-
sessed by trypan blue. Although the latter comprise a mi-
nority of the cells which died, there is no evidence that
their death occurred via a pathway dependent upon ICE
family proteases.
BD-FMK, but not ZVAD-FMK, Blocks Apoptotic Death in
the IL-2–dependent CTTL-2 Cell Line. Fig. 4 shows ex-
periments examining the ability of ZVAD-FMK and BD-
FMK to inhibit apoptotic death in the IL-2–dependent
murine T cell line CTTL-2. In these experiments we also
measured the binding of FITC-Annexin V to the mem-
brane, another nonnuclear apoptotic damage reflecting ex-
ternal phosphotidyl serine exposure (13). A previous report
showed that ICE inhibitors fail to block death mediated by
IL-2 withdrawal in this cell line (14). Fig. 4 confirms these
results with the ICE inhibitor ZVAD-FMK, which, like
ZFA-FMK, fails to block any of the death readouts in-
duced by dexamethasone (A–D), etoposide (E–H), or IL-2
withdrawal (I–L) in these cells. Unlike ZVAD-FMK, BD-
FMK inhibited CTLL-2 death with patterns quite similar
to those seen with thymocytes and lymphoblasts. Apoptotic
nuclear damage was completely inhibited by this reagent
while nonnuclear death criteria were in some cases less
completely blocked, reflecting the behavior seen with blasts.
Discussion
While blocking in vivo and in vitro programmed cell
death by expressing viral inhibitors of ICE family proteases
has given convincing evidence of their general functional
importance (1), such inhibitors are difficult to use experi-
mentally to implicate these proteases in many important
death systems. To probe T lymphocyte apoptotic death in
vitro, we have studied two different peptide-FMK reagents
designed to inactivate ICE family proteases. While further
work is clearly needed to define the family members reac-
tive with these reagents, the functional effects reported
here allow insight into the changes in functional death
pathways which accompany T cell differentiation. A com-
bination of these experiments with future biochemical
studies on ICE family proteases should lead to a more exact
definition of molecular death pathways in T cells.
Figure 3. Inhibition of the apoptotic death of murine T cell blasts by
peptide-FMKs. Splenic T cell blasts were cultured for 18 h in the pres-
ence of: dexamethasone (A–C); etoposide (D–F); after g-irradiation(G–I);
and immobilized anti-CD3 (J–L) in the indicated concentration of ZVAD-
FMK (circles), BD-FMK (squares) and ZFA-FMK (triangles). Cell death was
assessed by apoptotic nuclear morphology (top row), quantitation of sub-G0
DNA by flow cytometry staining (middle row) and with trypan blue (bot-
tom row).
Figure 4. BD-FMK, but not ZVAD-FMK, blocks apoptotic death in
CTLL-2 cells induced by several agents. Murine CTLL-2 cells were cul-
tured with ZVAD-FMK (circles), BD-FMK (squares), or ZFA-FMK (trian-
gles), and in the absence (dashed lines) or presence (solid lines) of the follow-
ing death stimuli: A–D, dexamethasone (50 mM); E–H, etoposide (10
mM) and I–L: IL-2 withdrawal for 18 h. Cell death was measured by apop-
totic nuclear morphology (A, E, I ), FACSÒ-analyzed sub-G0 DNA (B, F,
J), trypan blue staining (C, G, K); and FACSÒ-analyzed FITC-Annexin V
staining (D, H, L).2449 Sarin et al. Brief Definitive Report
Both ZVAD-FMK and BD-FMK contain aspartate in the
P1 position and are designed to irreversibly inactivate ICE
family cysteine proteases in intact cells by alkylating the active
site cysteine (7). Unlike other available peptide-based inhibi-
tors of ICE family proteases, these FMK reagents can penetrate
membranes readily because the aspartate carboxylate side
chain is esterified and is expected to undergo cytoplasmic
hydrolysis to the free aspartate derivative. Inactivation of a
cellular process by a P1 asp-containing peptide–FMK reagent,
but not a control reagent such as ZFA-FMK, shows that a
member of the ICE family is functionally required, based on
the unusual asp-peptide cleavage specificity of the ICE fam-
ily and the selectivity of FMK reagents for cysteine proteases.
Because ICE-like proteases may become activated and
in turn process CPP-32-like proteases (4, 5), it has been
suggested that ZVAD-FMK inhibits death by selectively
blocking the former (15). In support of this, 10 mM ZVAD-
FMK was reported not to inhibit the ability of such CPP-
32-like proteases to cleave poly-ADP-ribose polymerase
(15). However, the data of Fig. 1 suggest that ZVAD-FMK
could block death by directly inactivating CPP-32–like
members of the ICE family, and indicate that further stud-
ies with purified enzymes are required. Furthermore, Fig. 2
shows that the ICE inhibitor ZVAD-FMK and the non-
ICE inhibitor BD-FMK block thymocyte death about
equally well, suggesting that ZVAD-FMK’s ability to in-
hibit the ICE-like protease subfamily may not be the
mechanism by which it blocks death. Cysteine protease in-
hibitors containing only a P1 asp have been previously
shown to block some cell deaths (16, 17), but their reactiv-
ity with ICE family proteases remains to be established. In
contrast to BD-FMK, a more reactive chloromethyl ketone
analog blocks ICE (18). While more experiments are needed
to assess the activity of BD-FMK with other ICE-family
proteases, the results in Fig. 1 indicate that the ability of this
reagent to block cell death could be due to its ability to di-
rectly inactivate some CPP-32-like ICE-family proteases.
The similarity of the inhibition titration curves of thy-
mocyte death induced by the four independent input path-
ways tested in Fig. 2 is striking. In no case was significant
inhibition seen with the control ZFA-FMK, indicating that
asparatate at the P1 position is important. For apoptotic
morphology, half maximal inhibition occurred at 15–40
mM ZVAD-FMK or BD-FMK, while comparable inhibi-
tion of death assessed by PI required about twice as much
reagent. The similarity of the inhibition curves suggests that the
same ICE family protease is the target of these reagents in in-
hibiting these four separate input pathways of thymocyte death.
Peptide FMKs inhibit the apoptotic death of activated
peripheral T cells with a significantly different pattern than
was found in thymocytes. ZVAD-FMK blocks Fas-induced
death effectively, but has a variable effect on other death
pathways in blasts. These experiments show several novel
aspects of the role of ICE family proteases in T lymphocyte
apoptotic death. For a single input pathway such as corti-
costeroid, T cell maturation is accompanied by a markedly
diminished sensitivity to the ICE-inhibitor ZVAD-FMK,
while sensitivity to BD-FMK is largely maintained. This is
most readily explained by a shift in the particular ICE fam-
ily protease members functional in the death pathway as the
cells mature. However, in T cell blasts, the CD3-triggered
Fas death pathway maintains its sensitivity to ZVAD-FMK,
arguing that ICE-like target proteases are still expressed and
accessible to the reagent. Thus the linkages between the
different death signaling input pathways and ICE family
proteases undergo interesting, and hitherto unappreciated,
changes with differentiation of T cells.
The experiments with CTLL-2 in Fig. 4 show a more
dramatic example of the different behavior of BD-FMK
and ZVAD-FMK, with the latter completely ineffective in
blocking any manifestation of death triggered by any death
stimulus tested. These data are compatible with the findings
of Vasilakos et al. (14) using other ICE inhibitors on the
death of CTLL-2 cells by IL-2 withdrawal. However, our
findings indicate that this is a property of CTLL-2 cells more
than growth factor withdrawal, and our data with BD-
FMK indicate that other ICE-family proteases are part of all
these death pathways. The behavior of CTLL-2 cells appears
to be unusual among T cell death systems we have exam-
ined, and such ZVAD-FMK resistant apoptotic death pro-
cesses may be uncommon generally, as this reagent and related
ICE-specific inhibitors have been found to block a number
of nonlymphoid in vitro and in vivo death systems (19–23).
The findings presented here make two related but dis-
tinct points: (a) they argue strongly that ICE family pro-
teases comprise a common step(s) in the apoptotic death of
most T lymphoid cells triggered by distinct input pathways,
and (b) they show that death pathways in T cells at different
stages of differentiation seem to use different ICE family
members when death is triggered by the same input path-
way. Many important issues remain to be elucidated re-
garding the functional ICE family proteases including the
elements controlling their activation, interactions amongst
family members, and their functional substrates leading to
cell death. Our results show that peptide-FMK inhibitors of
ICE family proteases permit simple functional experiments
which can begin to shed light on some of these issues.
We would like to thank Drs. Charles Zacharchuk and David Segal for their helpful comments on the manu-
script.
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